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Abstract 
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity 
Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe 
asthma; however, there is currently more and more data showing promising results in the 
management also of chronic urticaria. We present a case series of 19 patients with chronic 
urticaria treated in a university department with omalizumab and give an overview of the 
existing literature comprising an additional 59 cases as well as a total of 139 patients 
enrolled in two randomized controlled trials comparing omalizumab with placebo. The 
collective evidence points to omalizumab as a safe and effective treatment option for 
patients with chronic urticaria who do not sufficiently respond to standard therapy as 
recommended by existing guidelines. 
 
Introduction 
Urticaria is a condition characterized by localized or widespread pruritic wheals that 
typically exist for no more than 24 h. By definition acute urticaria lasts no longer than 
six weeks, whereas chronic urticaria lasts longer, often several years. Chronic urticaria 
can be classified into several subtypes but these may have overlapping features [1]. 
Chronic urticaria that has no detectable cause is termed chronic idiopathic urticaria. 
Autoimmune urticaria is not a well-defined term but it is generally recognized that 
those with autoimmune urticaria have anti-IgG antibodies against the high-affinity IgE 
receptor (FcεRI) on mast cells and basophils or directly to IgE antibodies. These can be 
documented with the urticaria histamine release (HR) test. Autoimmune urticaria 
affects about one third of all patients with chronic urticaria [2].  
Case Rep Dermatol 2012;4:19–26 
DOI: 10.1159/000336205 
Published online: 
January 30, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
 
20 
H1 antihistamines are recommended as first-line therapy for chronic urticaria; 
leukotriene receptor antagonists are indicated as second-line therapy, whereas 
immunosuppressive drugs such as corticosteroids, azathioprine or cyclosporine A 
should be reserved for severe recalcitrant disease [3]. 
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-
affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of 
moderate to severe asthma. However, there is currently more and more data showing 
promising results in the management of patients suffering from other allergic 
conditions such as chronic urticaria [4]. Omalizumab is usually recommended when 
other systemic therapies have failed [3]. 
Here we present a case series of chronic urticaria patients in a university 
department treated with omalizumab and give an overview of the existing literature 
concerning omalizumab treatment of therapy-resistant chronic urticaria. 
Methods 
The cases reported herein were selected consecutively from the Department of Dermatology at 
Bispebjerg Hospital in Copenhagen. All patients were initially referred to the department with a 
diagnosis of urticaria and were considered eligible for this report if they began treatment with 
omalizumab for urticaria during the one-year period from November 2010 to October 2011. For each 
case, the type and duration of urticaria was recorded as well as any previous medical treatment. If 
available, the results of relevant serological markers including serum total IgE and the urticaria HR 
test were noted. A histamine release >16.5% was regarded as positive (Reflab, Copenhagen, 
Denmark). All patients were treated with omalizumab at an initial dose of 150 mg once every two 
weeks, which was the department’s standard dosing regimen. The clinical response to treatment with 
omalizumab was recorded and for each patient it was possible to score the individual response to 
treatment as: no response, partial response, or almost complete/complete resolution of symptoms 
during treatment. Furthermore, the duration and any side effects of omalizumab were recorded. 
The response to treatment in our case series was compared with reports from the existing English 
language literature retrieved from PubMed using the search terms: ‘urticaria’, ‘omalizumab’ and ‘anti-
IgE’. Cross-references were retrieved but this did not identify additional studies. Studies published by 
December 2011 were included. Three non-English case reports were identified but these were not 
further considered. 
Results 
A total of 19 patients (14 females) began treatment with omalizumab during the 
observation period (table 1). The mean age at the time of omalizumab initiation was 36 
years for females and 49 for males. The mean duration of disease at initiation of 
omalizumab in the sample was 21 months for females and 24 months for males (one 
male patient had a duration of nine years). A total of 12 patients (63%) were classified 
as having chronic idiopathic urticaria, six patients (32%) had chronic autoimmune 
urticaria demonstrated by a positive urticaria HR test, whereas one patient had delayed 
pressure urticaria. 
All patients had antihistamine-resistant disease and all but two had been treated 
with other systemic drugs; 14 (74%) with prednisolone, 7 (37%) with azathioprine, 
cyclosporine A and/or mycophenolate mofetil, and 6 (32%) with TNF-α inhibitors.  
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In total, 11 patients (58%) experienced almost complete or complete resolution of 
symptoms during treatment with omalizumab, whereas five (26%) experienced partial 
resolution; three patients (16%) had no benefit of the treatment and of these, one had 
to discontinue treatment due to side effects (nausea, headache and flu-like symptoms). 
However, in general, treatment was tolerated very well and only three patients (16%) 
reported side effects. These three patients were all females and among the youngest in 
the sample (15, 19 and 29 years of age). 
Discussion 
The present case series included 19 patients with therapy-resistant chronic 
urticaria. On an initial dose of omalizumab of 150 mg once every two weeks, a total of 
84% of the patients experienced resolution of symptoms to a degree that exceeded the 
effect of previous treatments. The symptomatic effect of the treatment occurred in 
many of the patients after one or just a few days and no serious side effects were 
reported. 
These data add to the growing body of evidence supporting the use of omalizumab 
as a safe and effective treatment option for chronic urticaria. Particularly, by December 
2011, to our knowledge, a total of 59 cases of chronic urticaria treated with 
omalizumab have been reported in the literature comprising five cases of solar 
urticaria, two cases of heat urticaria, two cases of cold urticaria, three cases of delayed 
pressure urticaria, three cases of urticaria factitia, three cases of cholinergic urticaria, 
40 cases of chronic idiopathic urticaria, and 16 cases of chronic autoimmune urticaria. 
Furthermore, a total of 139 patients have been enrolled in two randomized controlled 
trials comparing omalizumab with placebo (table 2) [5–30]. The first randomized trial 
was restricted to patients with IgE against thyroperoxidase; 27 patients were 
randomized to omalizumab and 22 to placebo [29]. The absolute mean decrease in the 
urticaria activity score (UAS) during the 24 weeks of treatment was 17.8 points in the 
experimental group and 7.9 points in the placebo group. According to the investigator’s 
global assessment, as many as 67% of the patients in the experimental group were 
assessed as having achieved complete resolution of symptoms during the study 
compared with only 4% in the placebo group. The second trial included 90 patients 
with chronic idiopathic urticaria randomized to one of three different doses of 
omalizumab (75, 300 or 600 mg) or to placebo [30]. The absolute mean decrease in the 
UAS four weeks after a single dose of omalizumab was 14.6 points in the group 
receiving 600 mg omalizumab, 19.9 points in the group receiving 300 mg omalizumab, 
9.8 points in the group receiving 75 mg omalizumab, and 6.9 points in the group 
receiving placebo. The mean decrease in the groups receiving 300 and 600 mg 
omalizumab was statistically significantly greater than in the placebo group. A total of 
28.6, 36.0, and 4.4% of the patients had complete resolution of urticaria symptoms 
after receiving a single dose of 600, 300 and 75 mg omalizumab, respectively. No 
patients in the placebo group had complete resolution of symptoms. Both randomized 
trials reported mild but rather frequent side effects such as diarrhoea, headache, 
dysmenorrhoea and upper respiratory tract infections that, however, did not differ in 
prevalence between the groups receiving active treatment and placebo.  
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The rapid improvement of urticaria symptoms reported in almost all previous cases 
treated with omalizumab indicates that IgE plays an important role in chronic urticaria. 
However, although anti-IgE mechanisms are thought to be the principal mode of action 
for omalizumab, several of the published cases support a role of other mechanisms 
such as induction of eosinophil apoptosis, downregulation of the inflammatory 
cytokines IL-2, IL-4, IL-13 and TNF-α, increase in the activity of CD4+ cells by ATP 
release, decrease in basophil releasability as well as a marked decrease in the 
expression of FcεRI [18, 20, 21, 25]. These observations offer an explanation for the 
successful results also among patients with low levels of IgE. 
The dosing of omalizumab for chronic urticaria is in many cases based on the 
recommendations for asthma, i.e. based on serum total IgE levels and the weight of the 
patient [4]. We saw a marked effect in most of our patients of treatment with 150 mg 
once every two weeks. In comparison, most of the previous cases were treated with a 
higher dose, predominantly with an initial dose of 300 mg, which was also the dose that 
produced the most marked clinical response in the experimental trials [30]. On the 
contrary, earlier published case reports, in general, overestimated the effect of 
omalizumab compared with the controlled trials, and also did not report side effects or 
scored them as negligible or absent. 
Despite an undeniable value of omalizumab for chronic urticaria, it is still not clear 
why the drug is effective in some patients and less so in others. Nevertheless, the 
collective evidence points to omalizumab as a safe and effective treatment option for 
patients with chronic urticaria who do not sufficiently respond to standard therapy as 
recommended by existing guidelines [3]. 
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Table 1. Characteristics of 19 consecutive patients with urticaria treated with omalizumab 
         
          Patient 
characteristics 
  Urticaria characteristics    Omalizumab treatment 
            No.  sex  age    type  AO  duration  HR test  IgE  previous treatment    duration  dose  effect  side effects 
                                                           
01  M  42    CIU  yes  2 m  negative    H1, Pred    02 m  150 mg/2 w  ↑↑  none 
02  F  30    CIU  yes  2 m  negative    H1, Pred    04 m  150 mg/2 w  ↑↑  none 
03  F  46    DPU  no  3 y  negative  098  H1, Aza, CsA, TNF-α    12 m  150 mg/2w  ↑  none 
04  F  29    CAU  yes  6 m  positive    H1, Pred    01 m  150 mg/2w  →  none 
05  M  66    CIU  no  5 m  negative    H1    06 m   150 mg/2 w  ↑↑  none 
06  F  51    CAU  no  2 m  positive    H1, Pred    07 m  150 mg/2w  ↑↑  none 
07  F  19    CIU  yes  2 m  negative    H1, Pred    01 m  150 mg/2w  →  nausea 
08  M  50    CAU  yes  2 m  positive  007  H1, Pred    04 m  150 mg/2w  ↑  none 
09  F  24    CIU  no  2 y  negative    H1, Pred, Mont, CsA    09 m  150 mg/2 w  ↑↑  headache 
10  F  29    CIU  no  3 y  negative    H1    02 m  150 mg/2 w  ↑↑  none 
11  F  37    CIU  no  2 y  negative  165  H1, Pred, TNF-α    07 m  150 mg/2 w  ↑↑  none 
12  F  46    CIU  no  8 m  negative    H1, H2, Pred, CsA    07 m  150 mg/2 w  ↑↑  none 
13  M  23    CIU  no  6 m  negative    H1, H2, Pred    02 m  150 mg/2 w  ↑↑  none 
14  M  62    CAU  no  9 y  positive  029  H1, CsA, TNF-α    09 m  150 mg/2 w  ↑↑  none 
15  F  32    CIU  yes  2 y  negative  159  H1, Pred, Aza, TNF-α    15 m  150 mg/2 w  ↑  none 
16  F  35    CIU  yes  3 m  negative    H1, Pred, CsA    12 m  150 mg/2 w  ↑  none 
17  F  47    CIU  no  5 m  negative    H1, Pred    02 m  150 mg/2w  ↑↑  none 
18  F  62    CAU  no  8 y  positive  105  H1, Aza, CsA, MMF, TNF-α   04 m  150 mg/2 w  ↑  none 
19  F  15    CAU  no  2 y  positive    H1, Pred, TNF-α    02 w  150 mg/2 w  →  nausea, 
headache* 
                                                           
Type: CIU = chronic idiopathic urticaria; DPU = delayed pressure urticaria; CAU = chronic autoimmune urticaria. AO = Angioedema. 
Duration: time from debut of symptoms until initiation of omalizumab (m = months; y = years). Dose: initial dose of omalizumab (w = weeks). 
Previous treatment: H1/H2 = antihistamines; Pred = prednisolone; Mont = montelukast; Aza = azathioprine; CsA = cyclosporine A; MMF = 
mycophenolate mofetil; TNF-α = TNF-α inhibitor. Effect: overall change in clinical symptoms after treatment with omalizumab; no response 
(→), partial (↑), almost complete/complete (↑↑) resolution of symptoms. * Patient had to discontinue omalizumab due to side effects. 
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Table 2. Studies of urticaria treated with omalizumab 
         
         
Study characteristics   Number of patients    Omalizumab treatment 
            1st author  year    SU  HU  CU  DPU  UF  ChU  CIU  CAU    ef-
fect 
side effects  dose  comment 
                               
                               
Case studies                               
Boyce [5]  2006       1              ↑↑↑  unknown  375 mg/2 w  the patient was 12 years of age 
Spector [6]  2007               2  1    ↑↑↑  unknown  varying  serum total IgE was between 9 and 2,557 
kU/l 
Güzelbey [7]  2008   1                  ↑↑↑  unknown  150 mg/4 w  baseline serum total IgE was 22 kU/l 
Godse [8]  2008               1      ↑↑↑  unknown  300 mg/4 w  baseline serum total IgE was 778 kU/l 
Metz [9]  2008             1        ↑↑↑  none  150 mg/4 w  complete resolution after 5 w of treatment 
Otto [10]  2009             1        ↑  unknown  300 mg/4 w  sweat collected by pilocarpine 
iontophoresis 
Magerl [11]  2010         1      7      ↑↑  few  varying  the patient with DPU responded only 
partially 
Vestergaard 
[12] 
2010               2      ↑↑↑  some  varying  one patient had abdominal side effects 
Krause [13]  2010           1          ↑↑↑  none  300 mg/2 w  symptoms recurred as drug was 
discontinued 
Waibel [14]  2010   1                  ↑  unknown  400 mg/2 w  UVB action spectrum improved more than 
UVA 
Romano [15]  2010               2      ↑↑↑  unknown  400 mg/2 w  SPT positivity maintained during treatment 
Bullerkotte 
[16] 
2010     1                ↑↑↑  none  450 mg/2 w  symptoms recurred when dose was 
lowered 
Sabroe [17]  2010             1        →  none  300 mg/2 w  baseline serum total IgE was 1,523 kU/ml 
Bindslev-
Jensen [18] 
2010         1            ↑↑↑  none  150 mg/2 w  marked decrease in basophil releasability 
Al-Ahmad [19] 2010                 3    ↑↑↑  none  300 mg/4 w  no symptoms 12 w after discontinuation 
Iemoli [20]  2010               1      ↑↑↑  unknown  300 mg/2 w  ↓ in TNF-α and IL-4; ↑ in IFN-γ 
Saavedra [21]  2011               1      ↑↑  none  300 mg/2 w  80% decrease in the expression of FcεRI 
Groffik [22]  2011               9      ↑↑  few  varying  effect is the average across all patients 
Metz [23]  2011   2  1  1  1  2          ↑↑  none  varying  five of seven patients responded completely 
Godse [24]  2011               5      ↑↑  few  300 mg/2–4 w the urticaria activity score (UAS) was used 
Sánchez-
Machín [25] 
2011               1      ↑↑↑  none  300 mg/2 w  increase in activity of CD4+ by ATP release 
Duchini [26]  2011   1                  →  unknown  150 mg/4 w  reactive to UVA and visible light but not 
UVB 
    Observational studies 
Kaplan [27]  2008                 12    ↑↑  none  varying  one patient was a nonresponder to 
treatment 
Ferrer [28]  2011               9      ↑↑  unknown  300 mg  basophil counts did not change significantly 
    Controlled trials 
Maurer [29]  2011                           patients had IgE against thyroperoxidase 
                  27      ↑↑  in 81.5%  varying  UAS decreased 17.8 points during treatment 
                  22      ↑  in 86.4%  placebo  UAS decreased 5.8 points during treatment 
Saini [30]  2011                           75 mg omalizumab not better than placebo 
                  21      ↑↑  in 47.6%  600 mg  UAS decreased 14.6 points during treatment 
                  25      ↑↑  in 48.0%  300 mg  UAS decreased 19.9 points during treatment 
                  23      ↑  in 34.8%  75 mg  UAS decreased 9.8 points during treatment 
                  21      ↑  in 47.6%  placebo  UAS decreased 6.9 points during treatment 
                               
                               
SU = Solar urticaria; HU = heat urticaria; CU = cold urticaria; DPU = delayed pressure urticaria; UF = urticaria factitia; ChU = cholinergic 
urticaria; CIU  =  chronic idiopathic urticaria; CAU  =  chronic autoimmune urticaria. Effect is overall change in  clinical symptoms after 
treatment with omalizumab; no response (→), partial (↑), almost complete (↑↑) or complete (↑↑↑) resolution of symptoms. w = Weeks. 
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